FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is conducting research on the new coronavirus infection (COVID-19) using our AI system "Cascade Eye". We are pleased to announce that we have listed 450 candidate compounds.

　This time, using the pathway map (announced on April 2020, 4) created using our drug discovery support AI system "Cascade Eye", we analyzed the papers on the molecules and genes contained in it. Approximately 24 types of existing drug diversion candidates were found.In ordinary drug discovery research, it is said that the probability of approval after clinical trials is about 450/1, suggesting that the search for candidate drugs using "Cascade Eye" will bring about significant efficiency. It was.In addition, of the 30000 species listed, about 450 species such as autophagy and anti-inflammatory related compounds are commercially available, and after undergoing appropriate clinical trials regarding their effects and side effects, they can be expected to be used as coronavirus therapeutic agents in the future. I think it is.

　Information analysis is essential to control the infectious disease pandemic.The map we provide can support efficient and speedy therapeutic drug development in leading institutions for infectious disease control through comprehensive treatise analysis.I would like to contribute as much as possible to the settlement of the situation as soon as possible.

■ FRONTEONew Coronavirus Infection Countermeasures "COMBAT COVID-19"about

FRONTEO is implementing measures against new coronavirus infections using our AI.Information on this matter and future activities will be released on the special website below.The pathway map created this time is widely open to pharmaceutical companies and public institutions so that it can be used for selecting therapeutic agents.

https://lifescience.fronteo.com/covid-19

■ Cascade Eyeabout　URL:https://lifescience.fronteo.com/pharmaceuticals/cascade-eye/

"Cascade Eye" is FRONTEO's natural language analysis AI engine "Concept Encoder (concept encoder)"^®, Concept encoder) ”is an AI system that analyzes papers and medical information and displays and visualizes important genes and molecules involved in diseases on a pathway map (path diagram showing relevance).By analyzing the papers on the molecules and genes shown on the map, it is possible to search for existing drug candidates.Since AI makes decisions without human beliefs or biases, it can be applied comprehensively to predicting efficacy and safety, in addition to discovering new targets and biomarkers that may be overlooked based on existing knowledge and experience. is.We believe that it will be useful for discovering therapeutic agents for diseases with high unmet medical needs and for selecting therapeutic agent candidates in a short period of time when a viral pandemic occurs.

■ Concept Encoderabout　URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (concept encoder)^®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) ”and“ concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,559,206).